Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma

NCT03128047 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT03128047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03128047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1
Overall status
Completed
Start date
April 6, 2017
Completion date
April 5, 2025
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, high grade glioma